

NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease - Pipeline Insight, 2020

<https://marketpublishers.com/r/NC57AF217504EN.html>

Date: February 2020

Pages: 106

Price: US\$ 2,000.00 (Single User License)

ID: NC57AF217504EN

Abstracts

This report can be delivered to the clients within 48-72 Hours

NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease Overview

'NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease Pipeline Insight, 2020' Report By DelveInsight Outlays Comprehensive Insights Of Present Clinical Development Scenario And Growth Prospects Across The NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease Market. A Detailed Picture Of The NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease Pipeline Landscape Is Provided, Which Includes The Disease Overview And NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease Treatment Guidelines.

The Assessment Part Of The Report Embraces In-Depth NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease Commercial Assessment And Clinical Assessment Of The NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease Pipeline Products From The Pre-Clinical Developmental Phase To The Marketed Phase.

In The Report, A Detailed Description Of The Drug Is Proffered Including Mechanism Of Action Of The Drug, Clinical Studies, NDA Approvals (If Any), And Product Development Activities Comprising The Technology, NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease Collaborations, Licensing, Mergers And Acquisition, Funding, Designations, And Other Product-Related

Details.

NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease Of Pipeline Development Activities

The Report Provides Insights Into:

All Of The Companies That Are Developing Therapies For The Treatment Of NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease With Aggregate Therapies Developed By Each Company For The Same.

Different Therapeutic Candidates Segmented Into Early-Stage, Mid-Stage And Late Stage Of Development For The NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease Treatment.

NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease Key Players Involved In Targeted Therapeutics Development With Respective Active And Inactive (Dormant Or Discontinued) Projects.

Drugs Under Development Based On The Stage Of Development, Route Of Administration, Target Receptor, Monotherapy Or Combination Therapy, A Different Mechanism Of Action, And Molecular Type.

Detailed Analysis Of Collaborations (Company-Company Collaborations And Company-Academia Collaborations), Licensing Agreement And Financing Details For Future Advancement Of NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease Market.

The Report Is Built Using Data And Information Traced From The Researcher's Proprietary Databases, Company/University Websites, Clinical Trial Registries, Conferences, SEC Filings, Investor Presentations, And Featured Press Releases From Company/University Web Sites And Industry-Specific Third-Party Sources, Etc.

NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease Analytical Perspective By DelveInsight

In-Depth NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease Commercial Assessment Of Products

This Report Provides A Comprehensive Commercial Assessment Of Therapeutic Drugs That Have Been Included, Which Comprises Of Collaborations, Licensing, And Acquisition Deal Value Trends. The Report Also Covers Company-Company Collaborations (Licensing/Partnering), Company-Academia Collaborations, And Acquisition Analysis In Both Graphical And Tabulated Form In A Detailed Manner.

NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease Clinical Assessment Of Products

The Report Comprises Of Comparative Clinical Assessment Of Products By Development Stage, Product Type, Route Of Administration, Molecule Type, And MOA Type Across This Indication.

SCOPE OF THE REPORT

The NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease Report Provides An Overview Of Therapeutic Pipeline Activity And Therapeutic Assessment Of The Products By Development Stage, Product Type, Route Of Administration, Molecule Type, And MOA Type For NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease Across The Complete Product Development Cycle, Including All Clinical And Nonclinical Stages.

It Comprises Of Detailed Profiles Of NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease Therapeutic Products With Key Coverage Of Developmental Activities, Including Technology, Collaborations, Licensing, Mergers And Acquisition, Funding, Designations And Other Product-Related Details

Detailed NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease Research And Development Progress And Trial Details, Results Wherever Available, Are Also Included In The Pipeline Study.

Coverage Of Dormant And Discontinued Pipeline Projects Along With The

Reasons If Available Across NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease.

REPORT HIGHLIGHTS

A Better Understanding of Disease Pathogenesis Contributing To The Development Of Novel Therapeutics For NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease.

In The Coming Years, The NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease Market Is Set To Change Due To The Rising Awareness Of The Disease, And Incremental Healthcare Spending Across The World; Which Would Expand The Size Of The Market To Enable The Drug Manufacturers To Penetrate More Into The Market.

The Companies And Academics That Are Working To Assess Challenges And Seek Opportunities That Could Influence NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease R&D. The Therapies Under Development Are Focused On Novel Approaches To Treat/Improve The Disease Condition.

A Detailed Portfolio of Major Pharma Players Who Are Involved In Fueling The NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease Treatment Market. Several Potential Therapies For NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease Are Under Investigation. With The Expected Launch Of These Emerging Therapies, It Is Expected That There Will Be A Significant Impact On The NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease Market Size In The Coming Years.

Our In-Depth Analysis Of The Pipeline Assets (In Early-Stage, Mid-Stage And Late Stage Of Development For The Treatment Of NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease) Includes Therapeutic Assessment And Comparative Analysis. This Will Support The Clients In The Decision-Making Process Regarding Their Therapeutic Portfolio By Identifying The Overall Scenario Of The Research And Development Activities.

KEY QUESTIONS

What Are The Current Options For NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease Treatment?

How Many Companies Are Developing Therapies For The Treatment Of NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease?

What Are The Principal Therapies Developed By These Companies In The Industry?

How Many Therapies Are Developed By Each Company For The Treatment Of NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease?

How Many NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease Emerging Therapies Are In Early-Stage, Mid-Stage, And Late Stage Of Development For The Treatment Of NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease?

Out Of Total Pipeline Products, How Many Therapies Are Given As A Monotherapy And In Combination With Other Therapies?

What Are The Key Collaborations (Industry-Industry, Industry-Academia), Mergers And Acquisitions, And Major Licensing Activities That Will Impact NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease Market?

Which Are The Dormant And Discontinued Products And The Reasons For The Same?

What Is The Unmet Need For Current Therapies For The Treatment Of NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease?

What Are The Recent Novel Therapies, Targets, Mechanisms Of Action And Technologies Developed To Overcome The Limitation Of Existing NR2E3

mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease Therapies?

What Are The Clinical Studies Going On For NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease And Their Status?

What Are The Results Of The Clinical Studies And Their Safety And Efficacy?

What Are The Key Designations That Have Been Granted For The Emerging Therapies For NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease?

How Many Patents Are Granted And Pending For The Emerging Therapies For The Treatment Of NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease?

Contents

1. REPORT INTRODUCTION

2. NR2E3 MUTATION-ASSOCIATED RETINAL DEGENERATION AND CEP290 MUTATION-ASSOCIATED RETINAL DISEASE

2.1. Overview

2.2. History

2.3. NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease Symptoms

2.4. Causes

2.5. Pathophysiology

2.6. NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease Diagnosis

2.6.1. Diagnostic Guidelines

3. NR2E3 MUTATION-ASSOCIATED RETINAL DEGENERATION AND CEP290 MUTATION-ASSOCIATED RETINAL DISEASE CURRENT TREATMENT PATTERNS

3.1. NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease Treatment Guidelines

4. NR2E3 MUTATION-ASSOCIATED RETINAL DEGENERATION AND CEP290 MUTATION-ASSOCIATED RETINAL DISEASE - DELVEINSIGHT'S ANALYTICAL PERSPECTIVE

4.1. In-depth Commercial Assessment

4.1.1. NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease companies collaborations, Licensing, Acquisition -Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis

4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis

4.1.2.3. NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease Acquisition Analysis

5. THERAPEUTIC ASSESSMENT

- 5.1. Clinical Assessment of Pipeline Drugs
 - 5.1.1. Assessment by Phase of Development
 - 5.1.2. Assessment by Product Type (Mono / Combination)
 - 5.1.2.1. Assessment by Stage and Product Type
 - 5.1.3. Assessment by Route of Administration
 - 5.1.3.1. Assessment by Stage and Route of Administration
 - 5.1.4. Assessment by Molecule Type
 - 5.1.4.1. Assessment by Stage and Molecule Type
 - 5.1.5. Assessment by MOA
 - 5.1.5.1. Assessment by Stage and MOA
 - 5.1.6. Assessment by Target
 - 5.1.6.1. Assessment by Stage and Target

6. NR2E3 MUTATION-ASSOCIATED RETINAL DEGENERATION AND CEP290 MUTATION-ASSOCIATED RETINAL DISEASE LATE STAGE PRODUCTS (PHASE-III)

7. NR2E3 MUTATION-ASSOCIATED RETINAL DEGENERATION AND CEP290 MUTATION-ASSOCIATED RETINAL DISEASE MID STAGE PRODUCTS (PHASE-II)

8. EARLY STAGE PRODUCTS (PHASE-I)

9. PRE-CLINICAL PRODUCTS AND DISCOVERY STAGE PRODUCTS

10. INACTIVE PRODUCTS

11. DORMANT PRODUCTS

12. NR2E3 MUTATION-ASSOCIATED RETINAL DEGENERATION AND CEP290 MUTATION-ASSOCIATED RETINAL DISEASE DISCONTINUED PRODUCTS

13. NR2E3 MUTATION-ASSOCIATED RETINAL DEGENERATION AND CEP290 MUTATION-ASSOCIATED RETINAL DISEASE PRODUCT PROFILES

- 13.1. Drug Name: Company
 - 13.1.1. Product Description
 - 13.1.1.1. Product Overview

- 13.1.1.2. Mechanism of action
 - 13.1.2. Research and Development
 - 13.1.2.1. Clinical Studies
 - 13.1.3. Product Development Activities
 - 13.1.3.1. Collaboration
 - 13.1.3.2. Agreements
 - 13.1.3.3. Acquisition
 - 13.1.3.4. Patent Detail
 - 13.1.4. Tabulated Product Summary
 - 13.1.4.1. General Description Table
- Detailed information in the report?

14. NR2E3 MUTATION-ASSOCIATED RETINAL DEGENERATION AND CEP290 MUTATION-ASSOCIATED RETINAL DISEASE KEY COMPANIES

15. NR2E3 MUTATION-ASSOCIATED RETINAL DEGENERATION AND CEP290 MUTATION-ASSOCIATED RETINAL DISEASE KEY PRODUCTS

16. DORMANT AND DISCONTINUED PRODUCTS

- 16.1. Dormant Products
 - 16.1.1. Reasons for being dormant
- 16.2. Discontinued Products
 - 16.2.1. Reasons for the discontinuation

17. NR2E3 MUTATION-ASSOCIATED RETINAL DEGENERATION AND CEP290 MUTATION-ASSOCIATED RETINAL DISEASE UNMET NEEDS

18. NR2E3 MUTATION-ASSOCIATED RETINAL DEGENERATION AND CEP290 MUTATION-ASSOCIATED RETINAL DISEASE FUTURE PERSPECTIVES

19. NR2E3 MUTATION-ASSOCIATED RETINAL DEGENERATION AND CEP290 MUTATION-ASSOCIATED RETINAL DISEASE ANALYST REVIEW

20. APPENDIX

21. REPORT METHODOLOGY

- 21.1. Secondary Research

21.2. Expert Panel Validation

List Of Tables

LIST OF TABLES

Table 1: NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease Diagnostic Guidelines

Table 2: NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease Treatment Guidelines

Table 3: Assessment Summary

Table 4: Company-Company Collaborations (Licensing / Partnering) Analysis

Table 5: NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease Acquisition Analysis

Table 6: Assessment by Phase of Development

Table 7: Assessment by Product Type (Mono / Combination)

Table 8: Assessment by Stage and Product Type

Table 9: Assessment by Route of Administration

Table 10: Assessment by Stage and Route of Administration

Table 11: Assessment by Molecule Type

Table 12: Assessment by Stage and Molecule Type

Table 13: Assessment by MOA

Table 14: Assessment by Stage and MOA

Table 15: Assessment by Target

Table 16: Assessment by Stage and Target

Table 17: NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease Late Stage Products (Phase-III)

Table 18: NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease Mid Stage Products (Phase-II)

Table 19: NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease Early Stage Products (Phase-I)

Table 20: Pre-clinical and Discovery Stage Products

Table 21: Inactive Products

Table 22: Dormant Products

Table 23: Discontinued Products

List Of Figures

LIST OF FIGURES

Figure 1: Disease Overview

Figure 2: History

Figure 3: Symptoms

Figure 4: Causes

Figure 5: Pathophysiology

Figure 6: Diagnostic Guidelines

Figure 7: Treatment Guidelines

Figure 8: NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease companies collaborations, Licensing, Acquisition -Deal Value Trends

Figure 9: Company-Company Collaborations (Licensing / Partnering) Analysis

Figure 10: NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease Acquisition Analysis

Figure 11: Assessment by Phase of Development

Figure 12: Assessment by Product Type (Mono / Combination)

Figure 13: Assessment by Stage and Product Type

Figure 14: Assessment by Route of Administration

Figure 15: Assessment by Stage and Route of Administration

Figure 16: Assessment by Molecule Type

Figure 17: Assessment by Stage and Molecule Type

Figure 18: Assessment by MOA

Figure 19: Assessment by Stage and MOA

Figure 20: Late Stage Products (Phase-III)

Figure 21: Mid Stage Products (Phase-II)

Figure 22: Early Stage Products (Phase-I)

Figure 23: Pre-clinical and Discovery Stage Products

Figure 24: Inactive Products

Figure 25: Dormant Products

Figure 26: Discontinued Products

Figure 27: Unmet Needs

I would like to order

Product name: NR2E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease - Pipeline Insight, 2020

Product link: <https://marketpublishers.com/r/NC57AF217504EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NC57AF217504EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

